Drs. John T Sinnott, Kami Kim, and Seetha Lakshmi, distinguished Infectious Diseases faculty at the University of South Florida, discuss updates to the 2019 Coronavirus pandemic. Dr. Sinnott begins by tracing the beginnings of the pandemic, from its sylvatic origins in bats likely through an intermediary vector (a pangolin) to its first human hosts. Dr. Sinnott follows the pandemic to America, and shares some of the early assessments about the threat of the disease which were unheeded. Next, Dr. Sinnott discusses our current understanding of the pathophysiology of the SARS-2 Coronavirus, including its route of infection in the human host. Dr. Kim next discusses the specifics of Coronavirus testing, including the proper use and interpretation of molecular and antibody-based tests. Dr. Lakshmi then discusses current Coronavirus-targeted therapies, including convalescent plasma, remdesivir, dexamethasone, and monoclonal antibody-based treatments. Dr. Sinnott closes by discussing post-COVID syndromes and how the pandemic will likely end.
Dr. Katzman reviews the importance of toxins in the manifestation of bacterial diseases. Bacterial toxins cause injury by producing tissue damage to the host during a bacterial infection. The different mechanisms by which bacterial toxins can produce injury are reviewed, including via intracellular and cell surface targets, membrane damage, superantigens, and involvement of the extracellular matrix. Dr. Katzman next reviews several well-known bacterial toxins, including Staphylococcal and Streptococcal toxins and Pseudomonas exotoxin A. Lastly, toxin therapies, such as toxoids and passive immunization are reviewed.
Dr. Anthony Cannella, Associate Director of Epidemiology at the James A Haley Veterans Hospital, presents a series of clinical cases from his years in infectious diseases practice. The cases are presented in a visual, interactive format. From a virtual session originally recorded on August 19, 2020.
Dr. Mercurio reviews antimicrobial susceptibility testing methods and explains how this data reported with culture results can be best used to make informed antibiotic treatment decisions. Dr. Mercurio begins by discussing the difference between MIC and MBC, and the misconceptions about MIC values for different antibiotic agents. Next, she reviews recent changes in the susceptibility breakpoints for several bacterial organisms, including Enterococcus spp., Staphylococcus aureus, Enterobacteriaceae, and Pseudomonas. Lastly, she reviews the resistance issues with the “SPACE/SPICE” bacteria as well as inducible clindamycin resistance, and closes with comments on heteroresistance issues in bacterial populations.
Dr. John Greene, Chief of Infectious Diseases at Moffitt Cancer Center, reviews disorders involving the gastrointestinal tract. Syndromes discussed include Cholera, traveller’s diarrhea, Typhoid fever, Salmonellosis, Campylobacter, pathogenic E coli, Echinococcosis, aeromonas, and Vibrio. Dr. Greene presents the topics in a fast paced, photo quiz format.
In a follow-up to his presentation recorded in May 2020, Dr. Oehler presents ten current coronavirus myths or assertions circulating online today and comments on their legitimacy or inaccuracy. Topics covered include the importance of wearing masks, the differences in types of masks for the public, whether recent protests led to increased cases of COVID-19 in those communities, the phenomenon of “COVID parties,” the adequacy of U.S. coronavirus testing, the long term effects of COVID-19, and whether a Coronavirus vaccine will be available by early 2021.
Dr. Toney reviews the epidemiology and management of Varicella Zoster infections. He first discusses the prevalence and clinical presentation of this herpesvirus family infection. He points out the importance of recognizing the prodrome in patients before the complete outbreak occurs. He goes on to discuss the clinical complications of VZV disease, including ophthalmologic, multi-dermatomal, and disseminated infections. He next discusses the treatment options available to manage Zoster infections. The subject of available Zoster vaccines is then discussed, with a focus on the newer Recombinant Zoster Vaccine (RZV). Lastly, Dr. Toney presents a couple of photo case-studies.
Dr. Baluch provides an overview of how to structure an infection control program for a hospital. She reviews the different types of infection control precautions (standard, contact, droplet, special, airborne). She also addresses specific situations such as with measles and with stem cell transplant patients and other immunocompromised individuals.